{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:26:08Z","timestamp":1789601168009,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["389891681"],"award-info":[{"award-number":["389891681"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["CP II 17\/00029"],"award-info":[{"award-number":["CP II 17\/00029"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","award":["Investigator-initiated study Grant"],"award-info":[{"award-number":["Investigator-initiated study Grant"]}],"id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Long-term treatment with up to 1.8\u00a0mg liraglutide improves cardiovascular and all-cause mortality in patients with type 2 diabetes at high risk for cardiovascular disease (CVD) and is currently under investigation in subjects without diabetes. Aim of our study was to investigate whether high dose (3\u00a0mg) short-term (5\u00a0weeks) treatment with liraglutide in obese patients with no overt type 2 diabetes affects metabolites, lipid and lipoprotein profile and components of activin\u2013follistatin axis in cardiovascular beneficial or detrimental way.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Research design and methods<\/jats:title>\n                <jats:p>Twenty obese patients participated in a randomized, placebo-controlled, cross-over, double-blind study and were administrated liraglutide 3\u00a0mg or placebo for 5\u00a0weeks. Metabolites, fatty acids, lipid\u2013lipoprotein profile and concentrations of activins and follistatins (250 parameters) were assessed in serum at start and completion of each treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Concentrations of important cardiovascular markers such as total, free and remnant cholesterol were reduced with liraglutide before and after adjusting for weight loss. Similarly, reductions in number of small and medium size LDL particles and in their total lipid concentration were observed with liraglutide and partially weight-loss related. Tyrosine levels were reduced and behenic acid levels were increased whereas only minor changes were observed in HDL, VLDL and IDL. Concentrations of activin AB and follistatin were significantly reduced in liraglutide-treated group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Treatment of obese patients without overt type 2 diabetes with high dose of liraglutide for a short period of time induces changes in lipid\u2013lipoprotein and hormonal profile that are suggestive of lower risk of atherosclerosis and CVD.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> ClinicalTrials.gov Identifier: NCT02944500. Study ID Number 2015P000327. Registered November 2016<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-019-0945-7","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T13:04:39Z","timestamp":1572527079000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial"],"prefix":"10.1186","volume":"18","clinical-trial-number":[{"clinical-trial-number":"nct02944500","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Natia","family":"Peradze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia M.","family":"Farr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Perakakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda","family":"L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Sala-Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3755-8158","authenticated-orcid":false,"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"key":"945_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.metabol.2018.10.010","volume":"92","author":"E Pilitsi","year":"2019","unstructured":"Pilitsi E, Farr OM, Polyzos SA, Perakakis N, Nolen-Doerr E, Papathanasiou AE, et al. Pharmacotherapy of obesity: available medications and drugs under investigation. Metab Clin Exp. 2019;92:170\u201392. https:\/\/doi.org\/10.1016\/j.metabol.2018.10.010 (Epub 2018\/11\/06).","journal-title":"Metab Clin Exp"},{"key":"945_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.metabol.2017.08.010","volume":"78","author":"J Upadhyay","year":"2018","unstructured":"Upadhyay J, Polyzos SA, Perakakis N, Thakkar B, Paschou SA, Katsiki N, et al. Pharmacotherapy of type 2 diabetes: an update. Metab Clin Exp. 2018;78:13\u201342. https:\/\/doi.org\/10.1016\/j.metabol.2017.08.010 (Epub 2017\/09\/19).","journal-title":"Metab Clin Exp"},{"key":"945_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13827","author":"OM Farr","year":"2019","unstructured":"Farr OM, Upadhyay J, Rutagengwa C, Prisco B, Ranta Z, Adra A, et al. Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: implications for plateauing weight loss in response to anti-obesity therapies. Diabetes Obes Metab. 2019. https:\/\/doi.org\/10.1111\/dom.13827 (Epub 2019\/07\/10).","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"945_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/ijo.2014.88","volume":"39","author":"TA Wadden","year":"2015","unstructured":"Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes. 2015;39(1):187. https:\/\/doi.org\/10.1038\/ijo.2014.88 (Epub 2014\/10\/15).","journal-title":"Int J Obes"},{"issue":"4","key":"945_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827 (Epub 2016\/06\/14).","journal-title":"N Engl J Med"},{"issue":"25","key":"945_CR6","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1093\/eurheartj\/ehx668","volume":"39","author":"HM Ahmed","year":"2018","unstructured":"Ahmed HM, Khraishah H, Cho L. Cardioprotective anti-hyperglycaemic medications: a review of clinical trials. Eur Heart J. 2018;39(25):2368\u201375. https:\/\/doi.org\/10.1093\/eurheartj\/ehx668 (Epub 2017\/12\/14).","journal-title":"Eur Heart J"},{"issue":"1","key":"945_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/dom.13487","volume":"21","author":"N Matikainen","year":"2019","unstructured":"Matikainen N, Soderlund S, Bjornson E, Pietilainen K, Hakkarainen A, Lundbom N, et al. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study. Diabetes Obes Metab. 2019;21(1):84\u201394. https:\/\/doi.org\/10.1111\/dom.13487 (Epub 2018\/08\/04).","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"945_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.pathol.2018.10.017","volume":"51","author":"SJ Nicholls","year":"2019","unstructured":"Nicholls SJ, Nelson AJ. HDL and cardiovascular disease. Pathology. 2019;51(2):142\u20137. https:\/\/doi.org\/10.1016\/j.pathol.2018.10.017 (Epub 2019\/01\/08).","journal-title":"Pathology"},{"issue":"9841","key":"945_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"B Mihaylova","year":"2012","unstructured":"Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(12)60367-5 (Epub 2012\/05\/23).","journal-title":"Lancet"},{"issue":"5","key":"945_CR10","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/ATVBAHA.114.303284","volume":"34","author":"RC Hoogeveen","year":"2014","unstructured":"Hoogeveen RC, Gaubatz JW, Sun W, Dodge RC, Crosby JR, Jiang J, et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014;34(5):1069\u201377. https:\/\/doi.org\/10.1161\/ATVBAHA.114.303284 (. Epub 2014\/02\/22).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"945_CR11","doi-asserted-by":"publisher","DOI":"10.2174\/0929867326666190201142321","author":"E Pappa","year":"2019","unstructured":"Pappa E, Elisaf M, Kostara C, Bairaktari E, Tsimihodimos V. Cardioprotective properties of HDL: structural and functional considerations. Curr Med Chem. 2019. https:\/\/doi.org\/10.2174\/0929867326666190201142321 (Epub 2019\/02\/05).","journal-title":"Curr Med Chem"},{"issue":"9634","key":"945_CR12","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S0140-6736(08)61076-4","volume":"372","author":"MJ McQueen","year":"2008","unstructured":"McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372(9634):224\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(08)61076-4 (Epub 2008\/07\/22).","journal-title":"Lancet"},{"issue":"1","key":"945_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12933-018-0672-5","volume":"17","author":"M Poreba","year":"2018","unstructured":"Poreba M, Rostoff P, Siniarski A, Mostowik M, Golebiowska-Wiatrak R, Nessler J, et al. Relationship between polyunsaturated fatty acid composition in serum phospholipids, systemic low-grade inflammation, and glycemic control in patients with type 2 diabetes and atherosclerotic cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):29. https:\/\/doi.org\/10.1186\/s12933-018-0672-5 (Epub 2018\/02\/18).","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"945_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/osp4.133","volume":"3","author":"L Engelbrechtsen","year":"2017","unstructured":"Engelbrechtsen L, Lundgren J, Wewer Albrechtsen NJ, Mahendran Y, Iepsen EW, Finocchietto P, et al. Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB. Obes Sci Pract. 2017;3(4):425\u201333. https:\/\/doi.org\/10.1002\/osp4.133 (Epub 2017\/12\/21).","journal-title":"Obes Sci Pract"},{"issue":"10","key":"945_CR15","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1210\/jc.2018-01056","volume":"103","author":"N Perakakis","year":"2018","unstructured":"Perakakis N, Mougios V, Fatouros I, Siopi A, Draganidis D, Peradze N, et al. Physiology of activins\/follistatins: associations with metabolic and anthropometric variables and response to exercise. J Clin Endocrinol Metab. 2018;103(10):3890\u20139. https:\/\/doi.org\/10.1210\/jc.2018-01056 (Epub 2018\/08\/08).","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"945_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/dom.13572","volume":"21","author":"N Perakakis","year":"2019","unstructured":"Perakakis N, Kokkinos A, Peradze N, Tentolouris N, Ghaly W, Tsilingiris D, et al. Follistatins in glucose regulation in healthy and obese individuals. Diabetes Obes Metab. 2019;21(3):683\u201390. https:\/\/doi.org\/10.1111\/dom.13572 (Epub 2018\/11\/06).","journal-title":"Diabetes Obes Metab"},{"key":"945_CR17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.metabol.2018.05.003","volume":"85","author":"N Perakakis","year":"2018","unstructured":"Perakakis N, Upadhyay J, Ghaly W, Chen J, Chrysafi P, Anastasilakis AD, et al. Regulation of the activins\u2013follistatins-inhibins axis by energy status: impact on reproductive function. Metab Clin Exp. 2018;85:240\u20139. https:\/\/doi.org\/10.1016\/j.metabol.2018.05.003 (Epub 2018\/05\/13).","journal-title":"Metab Clin Exp"},{"issue":"7","key":"945_CR18","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/s41591-018-0048-0","volume":"24","author":"R Tao","year":"2018","unstructured":"Tao R, Wang C, Stohr O, Qiu W, Hu Y, Miao J, et al. Inactivating hepatic follistatin alleviates hyperglycemia. Nat Med. 2018;24(7):1058\u201369. https:\/\/doi.org\/10.1038\/s41591-018-0048-0 (Epub 2018\/06\/06).","journal-title":"Nat Med"},{"key":"945_CR19","doi-asserted-by":"publisher","first-page":"15153","DOI":"10.1038\/ncomms15153","volume":"8","author":"E Latres","year":"2017","unstructured":"Latres E, Mastaitis J, Fury W, Miloscio L, Trejos J, Pangilinan J, et al. Activin A more prominently regulates muscle mass in primates than does GDF8. Nat Commun. 2017;8:15153. https:\/\/doi.org\/10.1038\/ncomms15153 (Epub 2017\/04\/30).","journal-title":"Nat Commun"},{"issue":"26","key":"945_CR20","doi-asserted-by":"publisher","first-page":"E5266","DOI":"10.1073\/pnas.1620013114","volume":"114","author":"JL Chen","year":"2017","unstructured":"Chen JL, Walton KL, Hagg A, Colgan TD, Johnson K, Qian H, et al. Specific targeting of TGF-beta family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proc Natl Acad Sci USA. 2017;114(26):E5266\u201375. https:\/\/doi.org\/10.1073\/pnas.1620013114 (Epub 2017\/06\/14).","journal-title":"Proc Natl Acad Sci USA"},{"key":"945_CR21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1708037114","author":"W Song","year":"2017","unstructured":"Song W, Owusu-Ansah E, Hu Y, Cheng D, Ni X, Zirin J, et al. Activin signaling mediates muscle-to-adipose communication in a mitochondria dysfunction-associated obesity model. Proc Natl Acad Sci USA. 2017. https:\/\/doi.org\/10.1073\/pnas.1708037114 (Epub 2017\/07\/26).","journal-title":"Proc Natl Acad Sci USA"},{"key":"945_CR22","doi-asserted-by":"publisher","first-page":"c869","DOI":"10.1136\/bmj.c869","volume":"340","author":"D Moher","year":"2010","unstructured":"Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869. https:\/\/doi.org\/10.1136\/bmj.c869 (Epub 2010\/03\/25).","journal-title":"BMJ"},{"issue":"1","key":"945_CR23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1161\/CIRCGENETICS.114.000216","volume":"8","author":"P Soininen","year":"2015","unstructured":"Soininen P, Kangas AJ, Wurtz P, Suna T, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet. 2015;8(1):192\u2013206. https:\/\/doi.org\/10.1161\/CIRCGENETICS.114.000216 (Epub 2015\/02\/19).","journal-title":"Circ Cardiovasc Genet"},{"issue":"2","key":"945_CR24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jchromb.2004.07.002","volume":"809","author":"I Bondia-Pons","year":"2004","unstructured":"Bondia-Pons I, Castellote AI, Lopez-Sabater MC. Comparison of conventional and fast gas chromatography in human plasma fatty acid determination. J Chromatogr B Anal Technol Biomed Life Sci. 2004;809(2):339\u201344. https:\/\/doi.org\/10.1016\/j.jchromb.2004.07.002 (Epub 2004\/08\/19).","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"24","key":"945_CR25","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1093\/bioinformatics\/bty528","volume":"34","author":"J Chong","year":"2018","unstructured":"Chong J, Xia J. MetaboAnalystR: an R package for flexible and reproducible analysis of metabolomics data. Bioinformatics. 2018;34(24):4313\u20134. https:\/\/doi.org\/10.1093\/bioinformatics\/bty528 (Epub 2018\/06\/30).","journal-title":"Bioinformatics"},{"key":"945_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2147\/PPA.S97383","volume":"10","author":"M Rondanelli","year":"2016","unstructured":"Rondanelli M, Perna S, Astrone P, Grugnetti A, Solerte SB, Guido D. Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus. Patient Prefer Adherence. 2016;10:407\u201313. https:\/\/doi.org\/10.2147\/PPA.S97383 (Epub 2016\/04\/14).","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"945_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","volume":"61","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61(4):427\u201336. https:\/\/doi.org\/10.1016\/j.jacc.2012.08.1026 (Epub 2012\/12\/26).","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"945_CR28","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.numecd.2014.06.010","volume":"24","author":"D Ariel","year":"2014","unstructured":"Ariel D, Kim SH, Abbasi F, Lamendola CA, Liu A, Reaven GM. Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight\/obese persons with prediabetes. Nutr Metab Cardiovasc Dis. 2014;24(12):1317\u201322. https:\/\/doi.org\/10.1016\/j.numecd.2014.06.010 (Epub 2014\/10\/05).","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"11","key":"945_CR29","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/dom.12133","volume":"15","author":"K Hermansen","year":"2013","unstructured":"Hermansen K, Baekdal TA, During M, Pietraszek A, Mortensen LS, Jorgensen H, et al. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes Metab. 2013;15(11):1040\u20138. https:\/\/doi.org\/10.1111\/dom.12133 (Epub 2013\/05\/21).","journal-title":"Diabetes Obes Metab"},{"key":"945_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.atherosclerosis.2019.07.007","volume":"288","author":"C Anholm","year":"2019","unstructured":"Anholm C, Kumarathurai P, Pedersen LR, Samkani A, Walzem RL, Nielsen OW, et al. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: a randomized trial. Atherosclerosis. 2019;288:60\u20136. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.07.007 (Epub 2019\/07\/22).","journal-title":"Atherosclerosis."},{"key":"945_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ijcard.2018.03.128","volume":"264","author":"G Pichler","year":"2018","unstructured":"Pichler G, Amigo N, Tellez-Plaza M, Pardo-Cea MA, Dominguez-Lucas A, Marrachelli VG, et al. LDL particle size and composition and incident cardiovascular disease in a South-European population: The Hortega-Liposcale Follow-up Study. Int J Cardiol. 2018;264:172\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.128 (Epub 2018\/04\/10).","journal-title":"Int J Cardiol"},{"issue":"23","key":"945_CR32","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1161\/CIRCULATIONAHA.115.016857","volume":"132","author":"S Mora","year":"2015","unstructured":"Mora S, Caulfield MP, Wohlgemuth J, Chen Z, Superko HR, Rowland CM, et al. Atherogenic lipoprotein subfractions determined by ion mobility and first cardiovascular events after random allocation to high-intensity statin or placebo: the justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) Trial. Circulation. 2015;132(23):2220\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.016857 (Epub 2015\/09\/27).","journal-title":"Circulation"},{"issue":"6","key":"945_CR33","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/MOL.0000000000000127","volume":"25","author":"AD Sniderman","year":"2014","unstructured":"Sniderman AD, Lamarche B, Contois JH, de Graaf J. Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB. Curr Opin Lipidol. 2014;25(6):461\u20137. https:\/\/doi.org\/10.1097\/MOL.0000000000000127 (Epub 2014\/10\/24).","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"945_CR34","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/CIRCULATIONAHA.113.005873","volume":"129","author":"S Mora","year":"2014","unstructured":"Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation. 2014;129(5):553\u201361. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.005873 (Epub 2013\/12\/19).","journal-title":"Circulation"},{"key":"945_CR35","doi-asserted-by":"publisher","first-page":"1273042","DOI":"10.1155\/2017\/1273042","volume":"2017","author":"EA Ivanova","year":"2017","unstructured":"Ivanova EA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN. Small dense low-density lipoprotein as biomarker for atherosclerotic diseases. Oxid Med Cell Longev. 2017;2017:1273042. https:\/\/doi.org\/10.1155\/2017\/1273042 (Epub 2017\/06\/03).","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"945_CR36","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1373\/clinchem.2009.137489","volume":"56","author":"M Ai","year":"2010","unstructured":"Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, et al. Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem. 2010;56(6):967\u201376. https:\/\/doi.org\/10.1373\/clinchem.2009.137489 (Epub 2010\/05\/01).","journal-title":"Clin Chem"},{"issue":"1","key":"945_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12933-018-0689-9","volume":"17","author":"SH Yang","year":"2018","unstructured":"Yang SH, Xu RX, Cui CJ, Wang Y, Du Y, Chen ZG, et al. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db\/db mice through a HNF-1a dependent mechanism. Cardiovasc Diabetol. 2018;17(1):48. https:\/\/doi.org\/10.1186\/s12933-018-0689-9 (Epub 2018\/04\/06).","journal-title":"Cardiovasc Diabetol"},{"issue":"18","key":"945_CR38","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1161\/CIRCULATIONAHA.113.002500","volume":"129","author":"C Stegemann","year":"2014","unstructured":"Stegemann C, Pechlaner R, Willeit P, Langley SR, Mangino M, Mayr U, et al. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation. 2014;129(18):1821\u201331. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.002500 (Epub 2014\/03\/14).","journal-title":"Circulation"},{"issue":"4","key":"945_CR39","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/ajcn\/nqz005","volume":"109","author":"AM Fretts","year":"2019","unstructured":"Fretts AM, Imamura F, Marklund M, Micha R, Wu JHY, Murphy RA, et al. Associations of circulating very-long-chain saturated fatty acids and incident type 2 diabetes: a pooled analysis of prospective cohort studies. Am J Clin Nutr. 2019;109(4):1216\u201323. https:\/\/doi.org\/10.1093\/ajcn\/nqz005 (Epub 2019\/04\/16).","journal-title":"Am J Clin Nutr"},{"issue":"21","key":"945_CR40","doi-asserted-by":"publisher","first-page":"e010019","DOI":"10.1161\/JAHA.118.010019","volume":"7","author":"RN Lemaitre","year":"2018","unstructured":"Lemaitre RN, McKnight B, Sotoodehnia N, Fretts AM, Qureshi WT, Song X, et al. Circulating very long-chain saturated fatty acids and heart failure: the cardiovascular health study. J Am Heart Assoc. 2018;7(21):e010019. https:\/\/doi.org\/10.1161\/JAHA.118.010019 (Epub 2019\/01\/05).","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"945_CR41","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1161\/ATVBAHA.118.312073","volume":"39","author":"C Papandreou","year":"2019","unstructured":"Papandreou C, Sala-Vila A, Galie S, Muralidharan J, Estruch R, Fito M, et al. Association between fatty acids of blood cell membranes and incidence of coronary heart disease. Arterioscler Thromb Vasc Biol. 2019;39(4):819\u201325. https:\/\/doi.org\/10.1161\/ATVBAHA.118.312073 (Epub 2019\/02\/08).","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"945_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12933-018-0701-4","volume":"17","author":"XM Chen","year":"2018","unstructured":"Chen XM, Zhang WQ, Tian Y, Wang LF, Chen CC, Qiu CM. Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):53. https:\/\/doi.org\/10.1186\/s12933-018-0701-4 (Epub 2018\/04\/11).","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"945_CR43","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.tem.2014.10.004","volume":"26","author":"EN Gurzov","year":"2015","unstructured":"Gurzov EN, Stanley WJ, Brodnicki TC, Thomas HE. Protein tyrosine phosphatases: molecular switches in metabolism and diabetes. Trends Endocrinol Metab. 2015;26(1):30\u20139. https:\/\/doi.org\/10.1016\/j.tem.2014.10.004 (Epub 2014\/11\/30).","journal-title":"Trends Endocrinol Metab"},{"issue":"18","key":"945_CR44","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1161\/CIRCULATIONAHA.111.067827","volume":"125","author":"S Cheng","year":"2012","unstructured":"Cheng S, Rhee EP, Larson MG, Lewis GD, McCabe EL, Shen D, et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation. 2012;125(18):2222\u201331. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.067827 (Epub 2012\/04\/13).","journal-title":"Circulation"},{"issue":"4","key":"945_CR45","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nm.2307","volume":"17","author":"TJ Wang","year":"2011","unstructured":"Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448\u201353. https:\/\/doi.org\/10.1038\/nm.2307 (Epub 2011\/03\/23).","journal-title":"Nat Med"},{"issue":"11","key":"945_CR46","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.tem.2015.09.003","volume":"26","author":"A Fountas","year":"2015","unstructured":"Fountas A, Diamantopoulos LN, Tsatsoulis A. Tyrosine kinase inhibitors and diabetes: a novel treatment paradigm? Trends Endocrinol Metab. 2015;26(11):643\u201356. https:\/\/doi.org\/10.1016\/j.tem.2015.09.003 (Epub 2015\/10\/24).","journal-title":"Trends Endocrinol Metab"},{"issue":"5","key":"945_CR47","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1210\/er.2014-1003","volume":"35","author":"Y Makanji","year":"2014","unstructured":"Makanji Y, Zhu J, Mishra R, Holmquist C, Wong WP, Schwartz NB, et al. Inhibin at 90: from discovery to clinical application, a historical review. Endocr Rev. 2014;35(5):747\u201394. https:\/\/doi.org\/10.1210\/er.2014-1003 (Epub 2014\/07\/23).","journal-title":"Endocr Rev"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0945-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-019-0945-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0945-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:17:03Z","timestamp":1628612223000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-019-0945-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,31]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["945"],"URL":"https:\/\/doi.org\/10.1186\/s12933-019-0945-7","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,31]]},"assertion":[{"value":"4 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed in Beth Israel Deaconess Medical Center (BIDMC) MA, USA, with prior approval of Institutional Review Board (IRB) from 2016 until\u00a02018. The study followed the Consolidated Standards of Reporting (CONSORT) guidelines and the International Conference on Harmonization for Good Clinical Practice [] (Additional file : Consort Flow Diagram).IRB of BIDMC reviewed and approved advertisement and fliers prior to use, as well as the informed consent forms. Personal information was collected according to the standardized ethics rules. After explaining the purpose and the procedures of the study and risks and benefits, a written informed consent was obtained for participation in this randomized, placebo-controlled, cross-over, double-blind study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have seen and read the material to be published and give the consent for publication to the Cardiovascular Diabetology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CSM has received consulting fees,\u00a0an investigator-initiated study grant from Novo Nordisk and research support through his institution, BIDMC, for investigator-initiated research. CSM is an\u00a0advisor of Ansh Labs LLC. Other authors have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}